Drug Development

As the world grapples with drug-resistant bacteria, an Israeli biotech is testing a novel drug that physically destroys pathogens. Can it turn the tide?

New data on Syndax Pharma's Revuforj shows a 90% survival rate in a high-risk leukemia group, signaling a potential paradigm shift and major market catalyst.

As its CEO heads to a top investor conference, Zealand Pharma leverages AI and novel peptides to challenge giants in the multi-billion-dollar obesity market.

As Rise Therapeutics advances its oral drug R-2487, it’s not just developing another pill. It’s testing a radical new idea: resetting the immune system.

Montara Therapeutics' new MJFF grant isn't just about Parkinson's. It's a bet on a 'BrainOnly' platform that could unlock a new era for CNS therapies.

A burgeoning market for cervical dystonia is set for disruption. A pipeline of novel therapies, including oral options, promises to address unmet patient needs.

With a fresh $31M, Advanced NanoTherapies is advancing a first-of-its-kind dual-drug nanoparticle balloon, a technology poised to disrupt the market.

Upcoming study results for Bayer's KERENDIA could unlock a new treatment for millions with non-diabetic chronic kidney disease, a vast and underserved group.

The FDA just granted Orphan Drug status to a promising ALS therapy. It's a beacon of hope for patients and a masterclass in biotech strategy.

With positive FDA feedback and an innovative digital trial design, Herantis Pharma's HER-096 moves closer to becoming a potential disease-modifying therapy.

With a seasoned drug developer at the helm, preclinical biotech FundaMental Pharma signals a major push to bring its novel TRD therapy through the clinical gauntlet.

Rakovina Therapeutics reports a dramatic financial recovery, slashing costs while boosting AI-driven R&D, positioning its promising cancer pipeline for growth.

As CEO Richard Francis prepares for a key address, Teva's 'Pivot to Growth' is under the microscope. Can innovation truly outpace its generics legacy?

Researchers have discovered a metabolic 'Achilles' heel' in a rare liver cancer, offering a new treatment path beyond ineffective chemotherapy.

A new drug targeting cancer's 'immortality switch' enters a pivotal trial, offering hope for non-small cell lung cancer patients out of options.

Facing a severe cash crunch, Jasper Therapeutics is exploring a sale or even a shutdown, placing the future of its promising urticaria drug, briquilimab, in limbo.

A novel drug for muscle loss in COPD patients has fully recruited its Phase 2 trial, a major step towards the first-ever treatment for sarcopenia.

A new drug combination delays cancer progression by over a year in advanced prostate cancer, offering new hope against treatment resistance, a new study finds.

New long-term data on pegcetacoplan offers significant hope for patients with rare, debilitating kidney diseases, strengthening Sobi's market position.

Haisco's Cipepofol gains US FDA approval, challenging Propofol with enhanced safety and signaling a new era of Chinese pharmaceutical innovation.